Ascendis Pharma A (ASND) Convertible Debt (2022 - 2025)

Ascendis Pharma A has reported Convertible Debt for 3 years, with the latest figure at $499.8 million in Q4 2025.

• Quarterly Convertible Debt rose 2.08% year-over-year to $499.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $499.8 million (up 2.08% YoY) and the FY2025 annual result came in at $499.8 million, up 2.08% from the prior year.
• Convertible Debt improved to $499.8 million in Q4 2025 per ASND's latest filing, from $489.6 million in the prior quarter.
• Over five years, Convertible Debt peaked at $499.8 million in Q4 2025 and troughed at $407.3 million in Q4 2022.
• A 3-year average of $465.6 million and a median of $489.6 million in 2024 frame the typical range for Convertible Debt.
• The widest YoY moves for Convertible Debt: up 2.08% in 2025, down 2.08% in 2025.
• Over 3 years, Convertible Debt stood at $407.3 million in 2022, then gained by 20.22% to $489.6 million in 2024, then climbed by 2.08% to $499.8 million in 2025.
• According to Business Quant data, Convertible Debt over the past three periods registered $499.8 million, $489.6 million, and $407.3 million for Q4 2025, Q4 2024, and Q4 2022 respectively.